237 related articles for article (PubMed ID: 25676845)
1. High-Grade Toxicity to Neoadjuvant Treatment for Upper Gastrointestinal Carcinomas: What is the Impact on Perioperative and Oncologic Outcomes?
Robb WB; Messager M; Gronnier C; Tessier W; Hec F; Piessen G; Mariette C;
Ann Surg Oncol; 2015 Oct; 22(11):3632-9. PubMed ID: 25676845
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70.
Blom RL; van Heijl M; Klinkenbijl JH; Bergman JJ; Wilmink JW; Richel DJ; Hulshof MC; Reitsma JB; Busch OR; van Berge Henegouwen MI
Dis Esophagus; 2013 Jul; 26(5):510-6. PubMed ID: 22925313
[TBL] [Abstract][Full Text] [Related]
3. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
Reynolds JV; Donohoe CL; McGillycuddy E; Ravi N; O'Toole D; O'Byrne K; Hollywood D
J Thorac Cardiovasc Surg; 2012 May; 143(5):1130-1137.e1. PubMed ID: 22244551
[TBL] [Abstract][Full Text] [Related]
4. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
5. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of postoperative mortality after junctional and gastric adenocarcinoma resection.
Robb WB; Messager M; Goere D; Pichot-Delahaye V; Lefevre JH; Louis D; Guiramand J; Kraft K; Mariette C;
JAMA Surg; 2013 Jul; 148(7):624-31. PubMed ID: 23552982
[TBL] [Abstract][Full Text] [Related]
7. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors.
Sauvanet A; Mariette C; Thomas P; Lozac'h P; Segol P; Tiret E; Delpero JR; Collet D; Leborgne J; Pradère B; Bourgeon A; Triboulet JP
J Am Coll Surg; 2005 Aug; 201(2):253-62. PubMed ID: 16038824
[TBL] [Abstract][Full Text] [Related]
8. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
9. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
12. The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.
Fuentes E; Ahmad R; Hong TS; Clark JW; Kwak EL; Rattner DW; Mullen JT
J Surg Oncol; 2016 Apr; 113(5):560-4. PubMed ID: 26792144
[TBL] [Abstract][Full Text] [Related]
13. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Gerber N; Ilson DH; Wu AJ; Janjigian YY; Kelsen DP; Zheng J; Zhang Z; Bains MS; Rizk N; Rusch VW; Goodman KA
Dis Esophagus; 2014 Apr; 27(3):235-41. PubMed ID: 23796070
[TBL] [Abstract][Full Text] [Related]
15. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
16. Adenocarcinoma of the esophagus and esophagogastric junction in patients older than 70 years: results of neoadjuvant radiochemotherapy followed by transthoracic esophagectomy.
Camerlo A; D'Journo XB; Ouattara M; Trousse D; Doddoli C; Thomas PA
J Visc Surg; 2012 Jun; 149(3):e203-10. PubMed ID: 22633088
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.
Coker AM; Barajas-Gamboa JS; Cheverie J; Jacobsen GR; Sandler BJ; Talamini MA; Bouvet M; Horgan S
J Laparoendosc Adv Surg Tech A; 2014 Feb; 24(2):89-94. PubMed ID: 24401141
[TBL] [Abstract][Full Text] [Related]
19. [Adenocarcinoma of the esophagogastric junction: retrospective analysis of 39 patients].
Butte JM; Becker F; Visscher A; Waugh E; Meneses M; Court I; Parada H; DE LA Fuente H
Rev Med Chil; 2010 Jan; 138(1):53-60. PubMed ID: 20361151
[TBL] [Abstract][Full Text] [Related]
20. Surgery of gastric cancer and esophageal cancer: Does age matter?
Nienhueser H; Kunzmann R; Sisic L; Blank S; Strowitzk MJ; Bruckner T; Jäger D; Weichert W; Ulrich A; Büchler MW; Ott K; Schmidt T
J Surg Oncol; 2015 Sep; 112(4):387-95. PubMed ID: 26303645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
